<DOC>
	<DOCNO>NCT01321541</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Pixantrone + Rituximab compare Gemcitabine + Rituximab patient relapse refractory diffuse large B-cell lymphoma ( DLBCL ) , follicular grade 3 lymphoma .</brief_summary>
	<brief_title>Comparison Pixantrone + Rituximab With Gemcitabine + Rituximab Patients With Aggressive B-cell Non-Hodgkin Lymphoma Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy Are Not Eligible Stem Cell Transplant</brief_title>
	<detailed_description>Eligible patient randomize treatment pixantrone plus rituximab gemcitabine plus rituximab six 28-day cycle . At time patient experience progressive disease study treatment , early follow- , intermediate follow-up , enter survival follow period . Patients complete study treatment discontinue study treatment reason participate follow-up period . Early Follow-Up : After treatment completion discontinuation , patient enter 24-week follow-up period . Intermediate Follow-Up : After complete 24-week early follow-up period , patient enter additional 72-week follow-up period . Survival Follow-Up : All patient monitor survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Diagnosis DLBCL ( de novo DLBCL , transform indolent lymphoma ) follicular grade 3 lymphoma basis tissue biopsy . 2 . Patients de novo DLBCL must receive 13 treatment regimen DLBCL . Patients follicular grade 3 lymphoma must receive 13 treatment regimen follicular lymphoma ( grade ) . Patients DLBCL transform indolent lymphoma must receive least 14 treatment regimen NHL . 3 . Received rituximab contain multiagent therapy treatment NHL . 4 . Not eligible highdose chemotherapy stem cell transplant . 5 . Patients DLBCL transform indolent lymphoma must complete partial response therapy NHL last least 12 week . 1 . Primary refractory de novo DLBCL primary refractory follicular grade 3 lymphoma , define document progression within 12 week last cycle firstline multiagent regimen . 2 . Prior treatment cumulative dose doxorubicin equivalent exceed 450 mg/m2 3 . Any experimental therapy â‰¤ 28 day prior randomization 4 . Other malignancy within last 5 year except follow : curatively treat basal cell/squamous cell skin cancer , carcinoma situ cervix , superficial transitional cell bladder carcinoma , situ ductal carcinoma breast complete resection 5 . Any contraindication know allergy hypersensitivity study drug 6 . Concomitant therapy anticancer agent , immunosuppressive agent , investigational anticancer therapy . Lowdose corticosteroid treatment non cancerrelated illness permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>non-hodgkin lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>relapse</keyword>
	<keyword>aggressive NHL</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Pixantrone</keyword>
	<keyword>NHL</keyword>
	<keyword>non hodgkin 's lymphoma</keyword>
	<keyword>de novo DLBCL</keyword>
	<keyword>DLBCL transform Indolent Lymphoma</keyword>
	<keyword>Follicular Grade 3 Lymphoma</keyword>
</DOC>